Lindus Health

Lindus Health is a biotechnology and healthcare company founded in 2021, headquartered in the United States. The company's slogan, "We are an anti-CRO running end-to-end clinical trials for life science pioneers," reflects its core mission of expediting the clinical trial process for the benefit of patients. Lindus Health operates with a unique commercial model that includes fixed-priced quotes per study and milestone-based payments, aligning incentives with its clients. This approach, combined with a world-class clinical operations team, a proprietary software platform, and access to 30 million Electronic Health Records, allows the company to run radically faster and more reliable clinical trials compared to traditional CROs. The company's end-to-end clinical trial services encompass study design, patient recruitment, clinical data capture, monitoring, and project management, thereby offering comprehensive support to its clients. Lindus Health has already assisted over 90 sponsors in running entire clinical studies across the US, UK, and Europe up to 3x faster than traditional CROs, with all trials delivered on or ahead of schedule. In August 2023, Lindus Health secured a $18.00M Series A investment from an impressive group of investors including Creandum, Firstminute capital, Seedcamp, Hambro Perks, Page One Ventures, Amino Collective, Calm/Storm, Peter Thiel. This investment reaffirms the investor community's confidence in Lindus Health's unique approach to accelerating clinical trials, and it provides the company with the necessary resources to further expand its impact in the life sciences industry.